Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

February 8, 2024

https://www.globenewswire.com/news-release/2024/02/08/2825996/0/en/Palisade-Bio-Announces-Formation-of-Clinical-Advisory-Board-with-Appointments-of-Preeminent-Key-Opinion-Leaders.html

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). Drs. Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.

Read more at globenewswire.com

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.